Can α-radioimmunotherapy increase efficacy for the systemic control of cancer?

Immunotherapy

Volumn 3, Issue 4, 2011, Pages 455-458

  Allen, Barry J ^a  

^a St George Cancer Care Centre   (Australia)

Author keywords

dosimetry; radiation; Ac:Bi generator cell clusters; isolated cancer cells; radioimmunotherapy; radioisotopes; tumors

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOCONJUGATE BI 213; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; CANCER CELL; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CAPILLARY PERMEABILITY; CLINICAL EFFECTIVENESS; DOSIMETRY; DRUG EFFICACY; EDITORIAL; GLIOBLASTOMA; HUMAN; MELANOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR VASCULARIZATION;

ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 79953828095     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.13     Document Type: Editorial

References (21)

1. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
2. Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43, 693-713 (2002).
3. Brons S, Jakob B, Taucher-Scholz G, Kraft G: Heavy ion production of single- and double-strand breaks in plasmid DNA in aqueous solution. Physica Medica XVII(Suppl. 1), 217-218 (2001).
4. Kerr JF: A histochemical study of hypertrophy and ischaemic injury of rat liver with special reference to changes in lysosomes. J. Path. Bact. 90, 419-435 (1965).
5. Martin VM, Sieqwert C, Scharl A et al.: Immunomagnetic enrichment of disseminated epithelial tumour cells from peripheral blood by MACs. Exp. Haem. 26, 252-264 (1998).
6. 213Bi-labeled multiple targeted α immunoconjugates. Prostate 66, 1753-1767 (2006).
7. Azzam EI, Little JB: The radiation-induced bystander effect: evidence and significance. Hum. Exp. Toxicol. 23, 61-65 (2004).
8. Allen BJ, Raja C, Rizvi SMA, Song EY, Graham P: Tumour anti-vascular α therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys. Med. Biol. 52, L15-L19 (2007).
9. Allen BJ, Goozee G, Sarkar S, Beyer G, Morel C, Byrne A: Production of terbium-152 by heavy ion reactions and proton induced spallation. App. Radiat. Isotopes 54, 53-58 (2000).
10. 211At-labeled chimeric anti-tenascin monoclonal antibody 81C6. J. Nucl. Med. 49(1) 30-38 (2008).
11. Melville G, Allen BJ: Cyclotron and linac production of Ac-225. App. Radiat. Isotopes 67(4) 549-555 (2009).
12. Koch L, Apostolidis C, Janssens W, Molinet R, van Geel J: Production of Ac-225 and application of the Bi-213 daughter in cancer therapy. Czech. J. Phys. 49(Suppl. 1), S817-S822 (1999).
13. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P et al.: Tumor therapy with targeted atomic nanogenerators. Science 294(5546), 1537-1540 (2001).
14. Song EY, Rizvi SMA, Raja C et al.: The cytokinesis-block assay as a biological dosimeter for targeted a therapy. Phys. Med. Biol. 53, 319-328 (2008).
15. Allen BJ: Clinical trials of targeted α therapy for cancer. Rev. Rec. Clin. Trials 3, 185-191 (2008).
16. Jurcic GJ, Larson SM, Sgouros G et al.: Targeted α particle immunotherapy for myeloid leukaemia. Blood 100, 1233-1239 (2002).
17. Raja C, Graham P, Rizvi SMA et al.: Interim analysis of toxicity and response in Phase 1 trial of systemic targeted α therapy for metastatic melanoma. Canc. Biol. Ther. 6(6), 846-852 (2007).
18. Allen BJ, Raja C, Rizvi SMA, Graham P, Kearsley JH: New directions for clinical trials of targeted α therapy for metastatic melanoma. Curr. Radio-Pharmaceut. 1, 240-250 (2008).
19. 213Bi-DOTA-[Thi8, Met(O2)11]-substance P: a pilot trial. Eur. J. Nucl. Med. Mol. Imaging 37, 1335-1344 (2010).
20. Schmidt D, Neumann F, Antke C et al.: Phase 1 Clinical Study on α-therapy for Non-Hodgkin Lymphoma. In: 4th Alpha-Immunotherapy Symposium. Morgenstern A, (Ed.). Institute for Transuranium Elements, Dusseldorf, Germany, 27-29 June 2004.
21. 2 - a Phase I study. J. Nucl. Med. 50(7), 1153-1160 (2009).